Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Antiinfective agent stubs
EICAR (antiviral)
Другие языки:

    EICAR (antiviral)

    Подписчиков: 0, рейтинг: 0
    Not to be confused with AICA ribonucleotide.
    EICAR
    EICAR.svg
    Clinical data
    Other names 5-Ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide
    Legal status
    Legal status
    Identifiers
    • 1-[(3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-ethynylimidazole-4-carboxamide
    CAS Number
    PubChem CID
    ChemSpider
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C11H13N3O5
    Molar mass 267.24 g·mol−1
    3D model (JSmol)
    • NC(=O)c1ncn(c1C#C)C2[C@H](O)[C@H](O)[C@H](O2)CO
    • InChI=1S/C11H13N3O5/c1-2-5-7(10(12)18)13-4-14(5)11-9(17)8(16)6(3-15)19-11/h1,4,6,8-9,11,15-17H,3H2,(H2,12,18)/t6-,8-,9-,11?/m1/s1
    • Key:SWQQELWGJDXCFT-ABHRNEANSA-N

    EICAR is a drug which acts as an inhibitor of the enzyme IMP dehydrogenase. It is a nucleoside derivative which has both anti-cancer and antiviral effects, and was originally developed for the treatment of leukemia, but was unsuccessful in human clinical trials. It has broad spectrum antiviral effects with activity against pox viruses, Semliki forest virus, Junin virus, reovirus, influenza, measles virus and respiratory syncytial virus among others, although it is not active against coronaviridae such as SARS-CoV-1. This useful spectrum of activity means that EICAR and related derivatives continue to be investigated for the treatment of viral diseases.



    Новое сообщение